Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.42 |
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23089187 | 0.80 | HPGD (0.57) | RAB9ANPC1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL21808418 | 0.80 | EGFR (0.47) | LMNA | |
| SCHEMBL25346779 | 0.79 | RAB9A (0.62) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL19457689 | 0.78 | KMT2A (0.36) | RAB9ANPC1KMT2ALMNAKDM4E | |
| SCHEMBL20265671 | 0.78 | KMT2A (0.40) | RAB9ANPC1KMT2AALDH1A1MAPK1 | |
| SCHEMBL21566100 | 0.76 | GSK3B (0.40) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL30075068 | 0.76 | GSK3B (0.40) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL23089552 | 0.75 | RAB9A (0.43) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL23089211 | 0.75 | RAB9A (0.43) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 | |
| SCHEMBL23089265 | 0.75 | RAB9A (0.44) | RAB9ANPC1KMT2AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3790883-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Aprinoia Therapeutics Inc. (TW) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019214681-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | RAB9A 603/4885NPC1 88/4885KMT2A 4329/4885 |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | RAB9A 603/4885NPC1 88/4885KMT2A 4329/4885 |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | RAB9A 603/4885NPC1 88/4885KMT2A 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.